GlassScriptPhysician profile
Howard S Kroop
NPI 1427027614
$4,257.97
in general payments reported to CMS, 2019-2025
26 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $161 · 2021: $709 · 2022: $774 · 2023: $608 · 2024: $458 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,485.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,534.99 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $579.09 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $365.06 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $251.84 | 2019-2021 | |
| Gilead Sciences, INC. | $239.57 | 2019-2025 | |
| Janssen Biotech, INC. | $197.15 | 2019-2024 | Stelara |
| Nestle Healthcare Nutrition INC. | $161.85 | 2020-2022 | |
| Pfizer INC. | $134.90 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $118.37 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $111.18 | 2019-2023 | Rebyota |
| Qol Medical, LLC | $106.88 | 2019-2022 | |
| Romark Laboratories, Lc | $70.77 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $64.54 | 2023 | |
| Merck Sharp & Dohme LLC | $64.14 | 2019 | |
| Allergan, INC. | $39.23 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $35.31 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $33.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $27.93 | 2019 | |
| Braintree Laboratories, INC. | $24.90 | 2019-2021 | |
| Organon LLC | $16.12 | 2023 | Renflexis, Hadlima |
| Shire North American Group INC | $14.98 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.62 | 2021 | |
| Redhill Biopharma INC. | $14.19 | 2023 | Aemcolo, Talicia |
| Ardelyx, INC. | $13.49 | 2022 | |
| Endo Pharmaceuticals INC. | $12.00 | 2019 | |
| Intercept Pharmaceuticals, INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Kroop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.